Published online 12 June 2008
Haematologica, Vol 93, Issue 8, 1273-1275 doi:10.3324/haematol.12567
Copyright © 2008 by Ferrata Storti Foundation
Falko H. Herrmann1 ,
Karin Wulff1 ,
Rüdiger Strey1 ,
Annelie Siegemund2 ,
Jan Astermark3 ,
Sam Schulman4 for the International Greifswald Registry of FVII deficiency*
This present study included 99 individuals heterozygous for A294V (52 males, mean age 33.4 years; 47 females, mean age 33.6 years). Their mean FVII level was 44±15%. Twenty-three (23%) and 76 (77%) heterozygous A294V carriers demonstrated or lacked spontaneous bleeding symptoms respectively. Nine of the 23 symptomatic heterozygous patients were sporadic cases; the others belonged to families (parents, siblings or children) of a FVII deficient index patient. 
* Members of the International Greifswald Registry of FVII deficiency, see appendix.
Haematologica, Vol 93, Issue 8, 1273-1275 doi:10.3324/haematol.12567
Copyright © 2008 by Ferrata Storti Foundation
Disorders of Hemostasis |
Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V
1 Institute of Human Genetics, Greifswald, Germany
2 Clinical Haemostaseology, University of Leipzig, Leipzig, Germany
3 Department for Coagulation Disorders, Malmö, University Hospital, Malmö, Sweden
4 Thrombosis Service, McMaster Clinic, HHS-General Hospital, Hamilton, Canada
Correspondence: Falko H. Herrmannn, University Greifswald, Medical Faculty, Institute of Human Genetics, Fleischmannstr. 42-44, D-17487 Greifswald, Germany. Phone: international +49.3834865371. Fax: international +49.3834865393. E-mail:herrmafh{at}uni-greifswald.de
Key words: factor VII deficiency, mutation A294V, clinical variability, endogenous thrombin potential.
Inherited factor VII deficiency (FVIID) is a rare autosomal bleeding disorder. Subjects with reduced FVII activity and identified F7 gene mutation are registered in the International Greifswald registry of FVIID.1 The mutation A294V is the most frequent among 717 FVIID patients in Central and North-Eastern Europe. The high prevalence of FVIID homozygous and heterozygous subjects, who share the same mutation (A294V), offers the unique possibility to study the clinical variability in a relatively large number of individuals with the identical defect in the F7 gene. In the reported study we have analyzed the clinical variability of 14 homozygous and 99 heterozygous subjects with F7 gene mutation A294V. Subjects with combinations with other bleeding disorders such as von Willebrand Disease, deficiency of FIX, FII etc., were excluded.
We collected data on factor VII clotting (FVII:C) activity, FVII antigen (FVII:Ag), date of initial onset of bleeding and bleeding symptoms.1,2
FVII:C was assayed locally with standard one-stage methods using thromboplastin (mostly recombinant and human-derived, Thromborel S® Dade Behring). FVII:Ag was measured at some of the centers using an immunoenzymatic method (Asserachrom, Diagnostica Stago, Asnieres, France). The following bleeding symptoms were evaluated according to published criteria:1–4 intracranial hemorrhage (ICH), gastrointestinal (GI) hemorrhage, hemarthrosis, subcutaneous hematoma as well as epistaxis, oral bleeding, and menorrhagia in accordance with Peyvandi and Mannucci.5 Endogenous thrombin potential (ETP) was measured in platelet poor plasma from controls and subjects homozygous for A294V in the presence of activated protein C.6 Citrated plasma samples from 8 control subjects without FVLeiden or FVHR2 (factor V wild type; FVwt) and without A294V mutation were used as a reference. We used the mutation H1299R as marker for FVHR2.7 The FVLeiden mutation was determined according to Bertina et al.8
The 14 homozygous subjects for the F7 gene mutation A294V are characterized by mean levels of FVII:C of 10±6% and of FVII:Ag of 52±11%. Nine of the homozygous patients (64%) had spontaneous bleeding symptoms (classified as symptomatic) and 5 (36%) did not (classified as asymptomatic). There was no significant difference in FVII level between symptomatic and asymptomatic homozygous A294V subjects.
The spontaneous bleeding profile of the 9 symptomatic subjects was characterized by GI (22%) bleeds, hemarthrosis (22%), epistaxis (33%), easy bruising (11%), gingival bleeding (22%), subcutaneous hematoma (11%), hematuria (22%), and menorrhagia (33%) but no ICH.
The thrombotic risk factor FVLeiden has already been reported to have a moderating effect on bleeding symptoms in patients with severe deficiency of factors VIII (hemophilia A),9 factor IX (hemophilia B)10 or with the mutation FVII g.9726+5G>A (FVIILazio).11 We analyzed the presence of the thrombophilia risk factors FVLeiden, FVHR2 and FIIG20210A mutation in 14 patients homozygous for A294V. In 3 out of 5 asymptomatic cases (60%) we found a co-inheritance for FVLeiden (heterozygous) or FVHR2 (heterozygous and homozygous). Among 9 symptomatic homozygous patients 8 had neither FVLeiden nor FVHR2 or FIIG20210A and only one case with mild bleeding characterized by occasional hematomas was heterozygous for the FVHR2 (p=0.09, Fisher exact test). These data suggest that the presence of FVLeiden or FVHR2 could attenuate the bleeding severity in homozygous A294V patients; however, due to the small size of patient population investigated, further studies are needed to clarify this. With a FVHR2 allele frequency of 7.4% in the German population, the frequency of 5.5% FVHR2 alleles among the symptomatic A294V patients matches the expected value, but the frequency of 30% FVHR2 alleles among the asymptomatic cases is above the expected value for a random selection. The high frequency of FVHR2 alleles suggests a moderating effect.
Recently we have shown an increased ETP in plasma samples from carriers of the mutations FVLeiden or FVHR2.6 On the basis of these findings we studied the ETP in available plasma samples from 9 FVII deficient patients, homozygous for A294V (Table 1). The ETP values of all seven plasma samples of symptomatic patients were significantly (p=0.002, Student’s t-test) lower than the reference value. Increased ETP values were only observed in the two samples of asymptomatic individuals. The ETP study supports a possible modulating influence of FVHR2 on differential clinical manifestations in homozygous A294V subjects. Further studies are required to confirm this trend.
|
View this table: [in a new window] [Download PPT slide] |
Table 1. Endogenous thrombin potential, bleeding symptoms and co-inheritance of FVHR2 in nine patients homozygous for the mutation A294V with available plasma samples.
|
The FVII level did not differ significantly between symptomatic and asymptomatic heterozygous A294V subjects. The prevalence of FVLeiden or FVHR2 was similar among the symptomatic and asymptomatic heterozygous cases. The bleeding pattern of the 23 heterozygous patients consisted of epistaxis (65%), gum bleeds (17%), easy bruising (30%), hematoma (3%), and menorrhagia (56% in women older than 14 years), but hemarthrosis, ICH or GI bleeding were not observed. Three patients (Online Supplementary Table S2) were treated as needed with pdFVII (patients f.10 and 9) or tranexamic acid (pt. 4).
In previously published papers, heterozygous probands were usually characterized as clinically asymptomatic and only single cases of heterozygous patients with clinical manifestations have been described.2,4 For some mutations (Arg304Gln) heterozygous subjects have moderate bleeding symptoms;4,12 but systematic studies of heterozygous subjects for F7 gene mutations do not exist. Our large-scale analysis of A294V heterozygous subjects shows that the proportion of symptomatic carriers of FVIID is relatively high.
Footnotes
* Members of the International Greifswald Registry of FVII deficiency, see appendix.
Funding: this work was partially supported by the German Federal Ministry for Education and Research (NBL3 program, reference 01 ZZ 0103). FH, KW, JA and SS are members of the IRF7, which is supported by Novo Nordisk.
References
 TOP References |
|---|
- Herrmann FH, Wulff K, Auberger K, Aumann V, Bergmann F, Bratanoff E, et al. Molecular biology and clinical manifestation of hereditary Factor VII deficiency. Semin Thromb Hemost 2000;26:393-400.[CrossRef][Web of Science][Medline]
- Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, et al. The International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005;93:481-7.[Web of Science][Medline]
- Wulff K, Herrmann FH. Twenty-two novel mutations of the Factor VII gene in Factor VII deficiency. Hum Mutat 2000;15:489-96.[CrossRef][Web of Science][Medline]
- Tuddenham EGD, Pemberton S, Cooper DN. Inherited factor FVII deficiency: genetics and molecular pathology. Thromb Haemost 1995;74:313-21.[Web of Science][Medline]
- Peyvandi F, Manunucci PM. Rare coagulation disorders. Thromb Haemost 1999;82:1207-14.[Web of Science][Medline]
- Strey RF, Siegemund A, Siegemund Th, Schubert Ch, Schuster G, Wulff K, Herrmann FH. Influence of Factor V HR2 on Thrombin Generation and Clinical Manifestation in Rare Bleeding disorders. Pathophysiol Haemost Thromb 2005;34:279-83.[CrossRef][Web of Science][Medline]
- Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, et al. A Factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-7.
[Abstract/Free Full Text] - Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.[CrossRef][Web of Science][Medline]
- Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, et al. Moderation of hemophilia A phenotype the factor VR506Q mutation. Blood 1996;88:1183-7.
[Abstract/Free Full Text] - Vianello F, Belvini D, Dal Bello F, Tagariello G, Zanon E, Lombardi A-M, et al. Mild bleeding diathesis in a boy with combined severe haemophilia B (C10400
T) and heterozygous factor V Leiden. Haemophilia 2001;7:511-4.[CrossRef][Web of Science][Medline] - Castoldi E, Govers-Riemslag JWP, Pinotti M, Biondini D, Tans G, Berrettini M, et al. Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation. Blood 2003;102:4014-20.
[Abstract/Free Full Text] - Cooper DN, Millar DS, Wacey A, Banner DW, Tuddenham EGD. Inherited factor FVII deficiency: molecular genetics and pathophysiology. Thromb Haemost 1997;8:151-60.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||